Please assess the completion status of the following clinical trial:

Trial Title: Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients 18 years of age and older~* admitted to surgical ICU~* diagnosed with hyperactive or mixed delirium~Exclusion Criteria:~* hypoactive delirium~* primary team does not think patient is appropriate to participate~* no oral access (PO or NGT)~* non-English speaking~* contraindication to study medications~* pregnant women or woman of child-bearing age not on documented contraception~* QTc = or greater than 480~* hepatic dysfunction~* decreased platelets or platelet dysfunction~* bleeding disorder, current major bleeding~* history of NMS, epilepsy, or PD~* diagnosis of schizophrenia, bipolar disorder or schizoaffective disorder~* on warfarin or carbapenems~* delirium due to alcohol withdrawal~* treated with antipsychotics for more than 48 hours prior to study enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valproic Acid (Type: EXPERIMENTAL): 1. Start:~   VPA PO/NGT 500 mg BID~2. If need to increase in 24 or more hours:~   VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3. If need to increase in 24 or more hours:~   VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4. If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN

Based on this trial design, predict the completion outcome and termination type (if applicable).